Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Integra LifeSciences Corporation
ClinicalTrials.gov Identifier:
NCT01060670
First received: January 31, 2010
Last updated: July 29, 2016
Last verified: July 2016

January 31, 2010
July 29, 2016
April 2010
June 2014   (final data collection date for primary outcome measure)
Incidence of Complete Wound Closure [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
100% closure as assessed by the Investigator and confirmed at 2 consecutive treatment phase visits.
Incidence of Complete Wound Closure [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01060670 on ClinicalTrials.gov Archive Site
  • Incidence of Complete Wound Closure [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Percentage of subjects with complete wound closure of the study ulcer, as assessed by computerized planimetry, during the treatment phase.
  • Time to Complete Wound Closure [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Measures the time to complete wound closure as assessed by the Investigator.
  • Time to Complete Wound Closure [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Time to complete wound closure, as assessed by computerized planimetry.
  • Rate of Wound Closure [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Rate of wound closure as assessed by computerized planimetry
  • Incidence of Ulcer Recurrence [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Measures the incidence of ulcer recurrence at the site of the study ulcer during the follow up phase.
  • Change in Short Form Health Survey (SF-36) Quality of Life Metrics [ Time Frame: Baseline and 16 weeks ] [ Designated as safety issue: No ]
    Short Form Health Survey (SF-36)- Quality of Life Metrics. The SF-36 was utilized and the Physical Function and Bodily Pain subscales were norm-based, with a Mean = 50, SD = 10. Scores could theoretically range from 0 to 100, with higher scores indicating a better health status.
  • Time to Complete Wound Closure [ Time Frame: 28 weeks ] [ Designated as safety issue: No ]
  • Incidence of recurrence [ Time Frame: 28 weeks ] [ Designated as safety issue: No ]
  • Incidence of adverse events [ Time Frame: 28 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers
A Multi-Center, Randomized, Controlled Clinical Trial to Evaluate The Safety and Effectiveness of Integra® Dermal Regeneration Template for the Treatment of Neuropathic Diabetic Foot Ulcers
The objective of this study is to evaluate the safety and efficacy of the INTEGRA® Dermal Regeneration Template for the treatment of diabetic foot ulcers located distal to the malleolus in subjects with diabetes mellitus, neuropathy, and without significantly compromised arterial circulation.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Neuropathic Diabetic Ulcer - Foot
  • Device: Integra® Dermal Regeneration Template
    Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
  • Other: Conventional Wound Therapy
    Conventional Wound Therapy
  • Experimental: Dermal Replacement Device
    Device: INTEGRA® Dermal Regeneration Template
    Intervention: Device: Integra® Dermal Regeneration Template
  • Active Comparator: Moist Wound Therapy
    0.9% Saline gel
    Intervention: Other: Conventional Wound Therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
545
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type I or Type II diabetes mellitus
  • Glycosylated hemoglobin, HbA1c, ≤ 12%
  • Negative serum pregnancy test at screening for female participants of child-bearing potential
  • Willing and able to maintain the required off-loading (as applicable for the location for the ulcer) and applicable dressing changes
  • At least one DFU that met the following criteria:

    1. Ulcer was diagnosed as a full-thickness neuropathic DFU that was located distal to the malleolus (excluding ulcers between the toes but including those of the heel),
    2. Minimum 2-cm margin between the qualifying study ulcer and any other ulcers on the specified foot (post debridement),
    3. Area greater than or equal to 1 square centimeter and less than or equal to 12 square centimeters (post debridement at the time of randomization),
    4. Wagner grade 1 or 2,
    5. Depth less than or equal to 5 millimeters with no exposed capsule, tendon or bone and no tunneling, undermining or sinus tracts,
    6. Duration of the study ulcer was at least 30 days at the time of the screening visit
  • Adequate vascular perfusion of the affected limb

Exclusion Criteria:

  • Suspected or confirmed signs/symptoms of gangrene or wound infection on any part of the limb
  • History of hypersensitivity to bovine collagen and/or chondroitin.
  • Pregnancy
  • Previous treatment under this clinical protocol
  • Participation in another clinical trial involving a device or systematically administered investigational study drug or treatment within 30 days of the randomization visit.
  • Receiving or scheduled to receive a medication or treatment which, in the opinion of the investigator, was known to interfere with, or affect the rate and quality of wound healing
  • Any unstable condition or circumstance that could interfere with treatment regimen compliance
  • Excessive lymphedema that could interfere with wound healing
  • Unstable Charcot foot or Charcot with boney prominence
  • Ulcers secondary to a disease other than diabetes
  • Osteomyelitis with necrotic soft bone
  • Chopart amputation
  • History of bone cancer or metastatic disease of the affected limb, radiation therapy to the foot, or chemotherapy within the 12 months prior to randomization
  • Treatment with wound dressings that include growth factors, engineered tissues, or skin substitutes within 30 days of randomization or scheduled to receive such treatment during the study
  • Non-study ulcer requiring treatment that could not be treated during the study with moist wound therapy
  • History of or intercurrent illnesses or conditions (other than diabetes) that would compromise the safety of the subject, or the normal wound healing process
  • Employees or relatives of any member of the investigational site or sponsor
  • Size of the study ulcer following debridement decreased by more than 30% during the run in period
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Netherlands Antilles
 
NCT01060670
IDRT/DFU US - 2009-3
No
Not Provided
Not Provided
Integra LifeSciences Corporation
Integra LifeSciences Corporation
Not Provided
Not Provided
Integra LifeSciences Corporation
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP